Zuoli Pharmaceutical (300181): Core products maintain steady growth in traditional Chinese medicine tablets
Zuoli Pharmaceutical (300181): Wuling capsules are growing at an impressive rate
Zuoli Pharmaceutical (300181): The growth rate of the Wuling series and Chinese medicine tablets is beautiful, and the repurchase of shares shows confidence in continuous operation
Zuoli Pharmaceutical (300181) Company Information Update Report: Outstanding Revenue and Profit Growth Rate, Rapid Release of the Wuling Series
Zuoli Pharmaceutical (300181) Company's First Coverage Report: Wuling+Bailing Dual Wheel Drive Builds Domestic Pharmaceutical Leader Geese
Zuoli Pharmaceutical (300181): 2024H1 performance exceeds expectations, core product growth continues
Zuoli Pharmaceutical (300181): 2024Q2 results continue high Q1 growth, and high growth is expected throughout the year with great certainty
Zuoli Pharmaceutical (300181): 2024 H1 performance exceeds market expectations and continued release of core products
Zuoli Pharmaceutical (300181): Wuling capsules benefit from a marked increase in collection volume, and the Bailing series begins new growth
Zuoli Pharmaceutical (300181) In-depth Research Report: Wuling Series Continues to Release, Bering Series Is Expected to Build a Second Growth Curve
Huaan Securities released a research report on April 21 stating that it gave Zoli Pharmaceutical (300181.SZ) a purchase rating. The main reasons for the rating include: 1) excellent performance in 23 and 24Q1, continuous optimization of cost ratios, and c
Zuoli Pharmaceutical (300181): 2024Q1 performance exceeds expectations, Wuling capsule growth rate is impressive
SDIC Securities released a research report on April 19 stating that it gave Zoli Pharmaceutical (300181.SZ) a purchase rating, and the target price was 18.25 yuan. The main reasons for the rating include: 1) the collection volume of Wuling capsules is obv
Zuoli Pharmaceutical (300181): The market space of the Wuling series is broad, and the launch volume of Bailing capsules can be expected
Dongfang Wealth Securities released a research report on April 19 stating that it gave Zoli Pharmaceutical (300181.SZ) an increase in holdings rating. The main reasons for the rating include: 1) core products returning to strong growth; 2) main products h
Zuoli Pharmaceutical (300181): Double increase in revenue and profit growth in 2024Q1
Zuoli Pharmaceutical (300181): Outstanding performance in 23 and 24Q1, the core product Wuling series continues to be released
Zuoli Pharmaceutical (300181): Continuing to promote new drug research and development with multiple measures to expand the out-of-hospital market
Zuoli Pharmaceutical (300181): Wuling Capsule's Secondary Development Dives Deep Product Potential, Bailing Capsule Approved to Reshape Second Growth Curve
Zuoli Pharmaceutical (300181) 2023 three-quarter report review: Short-term revenue side is under pressure and net profit continues to grow relatively well
No Data